24.87
price down icon0.96%   -0.24
after-market Dopo l'orario di chiusura: 24.87
loading
Precedente Chiudi:
$25.11
Aprire:
$24.88
Volume 24 ore:
676.68K
Relative Volume:
0.53
Capitalizzazione di mercato:
$15.96B
Reddito:
$2.62B
Utile/perdita netta:
$966.70M
Rapporto P/E:
16.58
EPS:
1.5004
Flusso di cassa netto:
$1.09B
1 W Prestazione:
+0.89%
1M Prestazione:
+10.04%
6M Prestazione:
+9.41%
1 anno Prestazione:
-10.57%
Intervallo 1D:
Value
$24.75
$25.00
Intervallo di 1 settimana:
Value
$24.28
$25.25
Portata 52W:
Value
$17.23
$27.91

Genmab Adr Stock (GMAB) Company Profile

Name
Nome
Genmab Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
2,638
Name
Cinguettio
@Genmab
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
GMAB's Discussions on Twitter

Confronta GMAB con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
GMAB
Genmab Adr
24.87 15.44B 2.62B 966.70M 1.09B 1.5004
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
391.02 100.52B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
580.70 61.43B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
446.51 59.29B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
712.20 43.09B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
306.05 35.42B 3.81B -644.79M -669.77M -6.24

Genmab Adr Stock (GMAB) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-01 Downgrade Bernstein Mkt Perform → Underperform
2025-03-11 Aggiornamento William Blair Mkt Perform → Outperform
2025-02-13 Aggiornamento Leerink Partners Market Perform → Outperform
2024-10-08 Iniziato Redburn Atlantic Buy
2024-09-04 Ripresa Morgan Stanley Equal-Weight
2024-08-20 Downgrade JP Morgan Overweight → Neutral
2024-07-15 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2024-02-23 Aggiornamento BMO Capital Markets Market Perform → Outperform
2024-01-22 Downgrade Citigroup Neutral → Sell
2023-12-06 Aggiornamento UBS Neutral → Buy
2023-11-10 Aggiornamento Deutsche Bank Hold → Buy
2023-11-08 Aggiornamento DNB Markets Sell → Buy
2023-10-18 Iniziato Exane BNP Paribas Underperform
2023-09-06 Downgrade RBC Capital Mkts Outperform → Sector Perform
2023-08-24 Iniziato BTIG Research Buy
2023-07-14 Iniziato HSBC Securities Buy
2023-05-31 Iniziato UBS Neutral
2023-05-12 Iniziato Morgan Stanley Underweight
2022-12-20 Downgrade Citigroup Buy → Neutral
2022-11-14 Iniziato William Blair Mkt Perform
2022-11-11 Downgrade Deutsche Bank Buy → Hold
2022-06-24 Iniziato BMO Capital Markets Market Perform
2022-05-02 Iniziato Cowen Market Perform
2022-03-16 Aggiornamento UBS Neutral → Buy
2022-01-31 Aggiornamento H.C. Wainwright Neutral → Buy
2022-01-03 Downgrade Guggenheim Buy → Neutral
2021-12-01 Iniziato Berenberg Sell
2021-09-16 Downgrade Jefferies Buy → Hold
2021-09-07 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-08-24 Downgrade H.C. Wainwright Buy → Neutral
2021-04-20 Iniziato Deutsche Bank Buy
2021-01-19 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-09-23 Downgrade Bryan Garnier Neutral → Sell
2020-09-08 Iniziato SVB Leerink Mkt Perform
2020-06-25 Downgrade Credit Suisse Outperform → Neutral
2020-04-23 Iniziato Credit Suisse Outperform
2020-02-24 Reiterato H.C. Wainwright Buy
2020-01-13 Iniziato SunTrust Buy
2019-12-12 Downgrade Deutsche Bank Buy → Hold
2019-09-13 Aggiornamento BofA/Merrill Neutral → Buy
2019-09-12 Aggiornamento JP Morgan Neutral → Overweight
2019-08-12 Iniziato Guggenheim Buy
2019-08-12 Iniziato Morgan Stanley Overweight
2019-08-12 Iniziato RBC Capital Mkts Outperform
Mostra tutto

Genmab Adr Borsa (GMAB) Ultime notizie

pulisher
Aug 27, 2025

Cresset Asset Management LLC Has $244,000 Stock Position in Genmab A/S Sponsored ADR $GMAB - Defense World

Aug 27, 2025
pulisher
Aug 27, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Aug 27, 2025
pulisher
Aug 22, 2025

IBD Rating Upgrades: Warrior Met Coal Shows Improved Technical Strength - inkl

Aug 22, 2025
pulisher
Aug 22, 2025

Genmab A/S (NASDAQ:GMAB) Cut to Hold at Zacks Research - Defense World

Aug 22, 2025
pulisher
Aug 21, 2025

IBD Rating Upgrades: Takeda Pharmaceutical ADR Shows Improved Technical Strength - inkl

Aug 21, 2025
pulisher
Aug 20, 2025

IBD Rating Upgrades: Ameren Shows Improved Technical Strength - inkl

Aug 20, 2025
pulisher
Aug 19, 2025

Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily

Aug 19, 2025
pulisher
Aug 19, 2025

SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors - GlobeNewswire Inc.

Aug 19, 2025
pulisher
Aug 19, 2025

IBD Rating Upgrades: Applied Indl Techs Shows Improved Relative Price Strength - inkl

Aug 19, 2025
pulisher
Aug 18, 2025

What is HC Wainwright’s Forecast for Genmab A/S Q1 Earnings? - Defense World

Aug 18, 2025
pulisher
Aug 18, 2025

BioNTech ADR Meets 80-Plus Relative Strength Rating Benchmark - inkl

Aug 18, 2025
pulisher
Aug 15, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by LPL Financial LLC - Defense World

Aug 15, 2025
pulisher
Aug 11, 2025

What is William Blair’s Forecast for Genmab A/S Q3 Earnings? - Defense World

Aug 11, 2025
pulisher
Aug 09, 2025

Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade - MSN

Aug 09, 2025
pulisher
Aug 08, 2025

Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail

Aug 08, 2025
pulisher
Aug 08, 2025

BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks

Aug 08, 2025
pulisher
Aug 07, 2025

GMAB: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com

Aug 07, 2025
pulisher
Aug 07, 2025

Genmab and BioNTech’s Promising Cancer Study: A Potential Game-Changer? - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Aug 07, 2025
pulisher
Aug 06, 2025

Genmab and BioNTech’s Innovative Cancer Trial: A Potential Game-Changer? - The Globe and Mail

Aug 06, 2025
pulisher
Aug 05, 2025

Genmab and BioNTech SE’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks

Aug 05, 2025
pulisher
Jul 24, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Stake Lessened by Cerity Partners LLC - Defense World

Jul 24, 2025
pulisher
Jul 24, 2025

Genmab and BioNTech Launch Promising Study for Advanced Colorectal Cancer Treatment - The Globe and Mail

Jul 24, 2025
pulisher
Jul 23, 2025

Genmab (GMAB) Upgraded to Strong Buy: Here's Why - MSN

Jul 23, 2025
pulisher
Jul 22, 2025

Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High? - Zacks Investment Research

Jul 22, 2025
pulisher
Jul 19, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by Envestnet Asset Management Inc. - Defense World

Jul 19, 2025
pulisher
Jul 17, 2025

Genmab Bets On Antibody Innovations As Royalties Rule The Day - Finimize

Jul 17, 2025
pulisher
Jul 16, 2025

Genmab A/S FY2025 EPS Estimate Increased by William Blair - Defense World

Jul 16, 2025
pulisher
Jul 11, 2025

Genmab AS (ADR) (US3723032062.SG) latest stock news and headlines - yahoo.co

Jul 11, 2025
pulisher
Jul 11, 2025

Genmab A/S (NASDAQ:GMAB) Price Target Raised to $46.00 - Defense World

Jul 11, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s Immunoradiotherapy Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 10, 2025
pulisher
Jul 09, 2025

Genmab and BioNTech’s Pioneering Cancer Trial: A Potential Game-Changer? - The Globe and Mail

Jul 09, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s Promising Immunoradiotherapy Study for Metastatic Tumors - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s GEN1056 Study: A Potential Game-Changer in Oncology - TipRanks

Jul 08, 2025
pulisher
Jul 06, 2025

Mirae Asset Global Investments Co. Ltd. Cuts Stock Position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World

Jul 06, 2025
pulisher
Jun 30, 2025

Envestnet Portfolio Solutions Inc. Sells 6,066 Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World

Jun 30, 2025
pulisher
Jun 19, 2025

GAMMA Investing LLC Boosts Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World

Jun 19, 2025
pulisher
Jun 02, 2025

Why Genmab Stock Smashed It On Monday - Barchart.com

Jun 02, 2025
pulisher
May 12, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

May 12, 2025
pulisher
May 09, 2025

Applied Dna Sciences Inc (APDN)’s Day in Review: Closing at 0.85, Down by -2.41 - DWinneX

May 09, 2025
pulisher
May 09, 2025

Stock Surge: Genmab ADR (GMAB) Closes at 19.42, Marking a -5.73 Increase/Decrease - DWinneX

May 09, 2025
pulisher
May 09, 2025

Market Momentum Report: Evercore Inc (EVR)’s Positive Close at 216.74 - DWinneX

May 09, 2025
pulisher
Apr 23, 2025

Investing in Take-Two Interactive Software, Inc (TTWO) Is Getting More Attractive - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

Investing in Genmab ADR (GMAB): What You Must Know - knoxdaily.com

Apr 23, 2025

Genmab Adr Azioni (GMAB) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$84.61
price up icon 1.09%
$23.70
price down icon 2.95%
$100.00
price down icon 1.89%
$136.10
price up icon 0.84%
biotechnology ONC
$306.05
price up icon 2.72%
Capitalizzazione:     |  Volume (24 ore):